申请人:Or Yat Sun
公开号:US20110064696A1
公开(公告)日:2011-03-17
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
本发明揭示了Formula (I)的化合物,或其药用可接受的盐、酯或前药:这些化合物抑制RNA含量的病毒,特别是丙型肝炎病毒(HCV)。因此,本发明的化合物干扰了丙型肝炎病毒的生命周期,同时也可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物,用于给患有HCV感染的受试者使用。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物、含有这些化合物的药物组合物以及用于治疗或预防受试者需要这种治疗的病毒(特别是HCV)感染的方法。